Gustave Roussy, Villejuif: Cancer Care and Patient Guide

Gustave Roussy traces its origins to cancer services developed in the early twentieth century and takes its name from physician and researcher Gustave Roussy. Its main campus is in Villejuif, in the Paris metropolitan area. The institution has developed around the integration of patient care, laboratory research and clinical investigation.

It is a non-profit specialist cancer centre with treatment, research and teaching functions. Rather than operating as a general hospital, it organises services around cancer diagnosis and management. Multidisciplinary assessment can involve medical oncologists, surgeons, radiation oncologists, pathologists, radiologists and other professionals, depending on the patient's needs.

The centre operates on a substantial scale, with services for adults and children and an extensive research portfolio. Its work includes complex cancers, molecular characterisation of tumours and development of new treatments. These institutional capabilities do not establish that every treatment is available for every diagnosis, or that care there would produce a better outcome than an appropriate alternative centre.

Breast cancer and lung cancer are prominent areas of care. Assessment considers the cancer subtype, stage, previous treatments and relevant biomarkers. Breast cancer planning may depend on hormone receptor and HER2 status, while lung cancer planning may include testing for molecular alterations and other markers that help guide systemic treatment. Local treatments and supportive care remain important alongside drug therapy.

Rare cancers and blood cancers are also part of the centre's specialist activity. Rare tumour assessment may require expert pathology review because classification can affect both treatment and trial eligibility. Blood cancers encompass several distinct diseases with different diagnostic and treatment pathways. Patients should ask whether the centre has an appropriate disease-specific team and whether the required service is available for their age group and diagnosis.

Treatment options include surgery, systemic anticancer medicines and radiation therapy, used alone or in combination where appropriate. The treatment goal may be cure, reducing recurrence risk, controlling disease or relieving symptoms. A proposed plan should explain the expected benefit, alternatives and potential effects on daily life.

Immunotherapy and targeted therapy are relevant to selected cancers, not universal substitutes for chemotherapy or other established care. Suitability depends on the tumour type, biological findings, previous treatment and the patient's overall health. Patients should distinguish an approved treatment offered as routine care from a treatment available only within research.

Precision oncology uses information about the cancer, including molecular profiling where appropriate, to help identify possible treatment options. Profiling does not always find an actionable alteration. Even when it does, a matching medicine may lack evidence for that cancer, be unavailable locally or require eligibility for a clinical trial.

Radiation therapy may form part of curative treatment or symptom management. The technique and schedule depend on the disease and clinical assessment. Supportive and palliative care can accompany anticancer treatment to address symptoms, treatment effects and quality of life.

The supplied profile describes around 500 active oncology clinical trials. This figure is indicative: trial portfolios change, and 'active' can include studies that are no longer enrolling new participants. DITEP, the centre's early-phase trials department, evaluates investigational approaches, including treatments being studied for safety, dosing and preliminary evidence of activity. Early-phase participation does not guarantee clinical benefit.

International patients can ask the international patients department how to obtain a specialist review for possible trial consideration. Assessment may require pathology, molecular results, treatment history, recent imaging and laboratory tests. Eligibility can depend on organ function, previous therapies, treatment-free intervals and availability of a study place. Screening may involve additional tests and visits. Patients should clarify which research-related and routine-care costs are covered, and whether repeated stays in France would be necessary.

Before travelling, request a review of the medical records and confirmation of the purpose of the proposed visit: a second opinion, further investigations, treatment or trial screening. Ask whether additional pathology review or testing is required and whether any of this can be completed locally. Do not interrupt current treatment without agreement from the treating team.

Compare the proposed pathway with suitable care available at home, including the burden of travel and time away from support networks. Obtain a written estimate and clarify payment or insurance requirements. Agree who will manage complications, prescriptions and follow-up after returning home, and how information will be shared with the local oncology team.

Contact details below come from the hospital's own published international patient information.

Location: Villejuif, France

Email: patients.international@gustaveroussy.fr

Phone: +33 1 42 11 42 11

Website: https://www.gustaveroussy.fr

Languages supported: French, English, Russian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.